Research trends on causes of Kawasaki disease in the COVID-19 era: focus on viral infections

Young Hwan Lee, MD
Department of Pediatrics, Yeungnam University College of Medicine, Daegu, Korea

Despite studies on the etiology of Kawasaki disease (KD) ongoing for half a century since its discovery, its cause has not yet been clearly identified. Although the clinical, epidemiological, and pathophysiological characteristics of KD are presumed to be closely related to infectious diseases, studies of various pathogens to identify its etiology have been actively conducted. To date, bacteria, fungi, and viruses have been investigated to determine the relationship between KD and infection, among which viruses have attracted the most attention. In particular, during the coronavirus disease 2019 pandemic, there were many reports in Europe of a sharp increase in cases of Kawasaki-like disease (KLD), while conflicting reports that the prevalence of KD decreased due to thorough “social distancing” or “wearing mask” in Asian countries drew more attention regarding the association between KD and viral infection. Therefore, the differential diagnosis of KD from KLD with these similar spectra has become a very important issue; simultaneously, research to solve questions about the association between KD and viral infection, including sudden acute respiratory syndrome coronavirus 2, is drawing attention again. Moreover, a new concept has emerged that immune responses occurring in patients with KD can be caused by the pathogen itself as well as host cells damaged by infection. This paper summarizes the research trends into KD etiology and related pathophysiology, especially its association with viral infections, and present future research tasks to increase our understanding of KD.

Key words: Kawasaki disease, Viral infection, Viruses, Etiology

Key message
- The etiology of Kawasaki disease (KD) is unclear, but its clinical, epidemiological, and pathophysiological characteristics are strongly associated with infectious diseases.
- In the coronavirus disease 2019 pandemic era, viruses are attracting the most attention. Sudden acute respiratory syndrome coronavirus 2 infection causes various hyperinflammation in children that require differentiation from KD.
- Immune responses in patients with KD may be induced by host cell damage. To effectively prevent and treat KD, the genetic background and immune responses of KD patients and triggering pathogens require identification.

Introduction

Although the coronavirus disease 2019 (COVID-19) pandemic has hampered daily life, it has shed new light on many aspects. The emergence of new diseases always intimidates people but occasionally aids the development of a new approach to the study of diseases that have remained unsolved.

Kawasaki disease (KD) is an acute systemic vasculitis that mainly manifests in children aged <5 years whose diagnosis usually depends on its clinical manifestations. KD is related to the patient's genetic sensitivity and risk of infection, and although various studies have examined its etiology for more than half a century since its introduction by Tomisaku Kawasaki in 1967, it has yet to be clarified.

Kawasaki-like disease (KLD), also known as multisystem inflammatory syndrome in children (MIS-C), was reported for the first time in Europe last year in pediatric patients with COVID-19. Although MIS-C shares some clinical features with KD, the 2 conditions are distinct. However, the reemergence of MIC-C reminded us of the apparent but unconfirmed association between KD and COVID-19 infection and raised expectations about KD pathology finally being resolved.

Recent reports showed that the incidence of KD significantly decreased versus that in the same period during the COVID-19 pandemic, when mask wearing and social distancing were implemented in Asian countries, where the KD prevalence was high. In contrast, the number of KLD cases has significantly increased in the United States, Italy, and the United Kingdom, where COVID-19 was more prevalent. These conflicting phenomena raised the expectation that the association between KD and viral infections could be confirmed. Therefore, this
study briefly summarizes the trends and results of research on the possible association between KD and infectious diseases, especially viral infections.

**Research on cause of KD**

In previous studies, KD was not controversial because abnormal immune responses in individuals with certain genetic backgrounds after infection are important mechanisms. Although KD is considered highly associated with infectious diseases in clinical, epidemiological, and pathophysiological aspects, its pathology is among the most notable research topics.

Table 1 summarizes the evidence suggesting a connection between KD and infection. First, most clinical symptoms included in the diagnostic criteria for KD (such as acute fever, skin rash, conjunctival injection, redness of the oral mucosa including strawberry tongue, and lymphadenitis) as well as accompanying respiratory symptoms are similar to those of acute infectious diseases. Epidemiologically, it is common in young children aged <5 years who are vulnerable to infections, and considering its occurrence in siblings of affected children, the high prevalence rate in countries in Northeast Asia, and the marked seasonal variations, it is believed to be an infectious disease characterized by epidemics. Recently, studies using big data and time series analysis of disease statistics have reported that various viral infection outbreaks precede KD. Moreover, pathophysiologically, the pattern of explosive systemic vasculitis in the acute phase is associated with microbial toxins or superantigens, and the fact that systemic vasculitis is sometimes self-limiting is similar to viral infectious diseases. Immunologically, the initial neutrophilic predominance in peripheral blood and arterial tissues in KD is compatible with an innate immune response to acute infection.
Research on KD-associated infectious pathogens

Although the exact cause of KD remains unknown, studies are underway. To identify the pathogen that causes a certain disease, some conditions must be met. According to Nagata,1 if an infectious pathogen has the potential to induce KD, it should (1) frequently be detected in KD patients, (2) be associated not only with clinical symptoms of KD disease, (3) have a coronary artery lesion induction mechanism, and (4) have an epidemiological association.

Nagata1 recently categorized 4 main theories about KD etiology: (1) direct infectious vasculitis, (2) autoantigen, (3) superantigen, and (4) RNA virus. However, none of these studies have been able to justify this epidemic.

To date, a wide variety of bacteria20-29 and viruses30-50 as well as the occasional fungus51,52 have been reported as KD-associated infectious pathogens (Table 2). Studies of most KD-associated pathogens are based on the theory that these pathogens act as antigens or even superantigens in genetically sensitive individuals that result in inappropriate immune responses rather than directly infecting individuals.

First, Staphylococcus and Streptococcus species are at the center of the superantigen theory, which has attracted attention related to KD pathogenesis. Leung et al.20 confirmed that the selective expansion of Vβ2+ T cells in most KD patients may be caused by Staphylococcus and Streptococcus species. Matsubara and Fukaya23 provided the following evidence of Staphylococcus and Streptococcus superantigens in the KD pathogenesis: the skewed distribution of the Vβ repertoire, superantigen-producing bacteria isolated from KD patients, serological responses to superantigens produced by Staphylococcus aureus, and Group A Streptococcus from case-control studies. Animal models have demonstrated the hallmarks of a superantigen-mediated response. In addition,

Table 2. Major pathogens reported as related to Kawasaki disease infection

| Types          | Pathogens                                                                 |
|----------------|---------------------------------------------------------------------------|
| Bacteria       | Staphylococcus aureus, Group A Streptococcus, Streptococcus pyogenes, Yersinia pseudotuberculosis, Klebsiella pneumoniae, Pseudomonas aeruginosa, Chlamydiae pneumoniae, Mycoplasma pneumoniae, Rickettial organisms |
| Viruses        | Adenovirus, Epstein-Barr virus, Human parvovirus B19, Herpesvirus 6, Varicella-zoster virus, Human bocavirus, Torque teno virus, Rotavirus, Enterovirus, Dengue virus, Parainfluenza type 3 virus, Human coronavirus NL63/OC43/229E/HKU1, Human metapneumovirus, Measles virus, Influenza A (H1N1), Severe respiratory syndrome coronavirus 2 (COVID-19) |
| Reverse transcribing viruses | Human immunodeficiency virus |
| Fungi          | Candida species, Candida albicans |

Table 3. Summary of characteristics of studies of bacteria as Kawasaki disease-related pathogens

| Study           | Pathogens                           | Study details                                      | Results/conclusions                                                                 |
|-----------------|-------------------------------------|-----------------------------------------------------|--------------------------------------------------------------------------------------|
| Leung et al.20  | Staphylococcus aureus, Streptococcus pyogenes | Control study 16 Acute KD patients & 15 controls | Selective expansion of Vβ2 + T cells in most patients with KD may be caused by a toxic shock syndrome toxin-producing S. aureus, and in a minority of patients, SPEB-producing or SPEC-producing streptococci. |
| Matsubara and Fukaya23 | Group A Streptococcus, Staphylococcus aureus | Review recent publications Total number of known staphylococcal superantigens to over 20 and streptococcal superantigens to 12 | Evidences support the involvement of superantigens in the pathogenesis of KD: - the skewed distribution of the Vβ repertoire; - superantigen-producing bacteria has been isolated from KD patients; - the serological responses to superantigens produced by S. aureus and GAS from case-control studies; and - animal models have demonstrated all the hallmarks of a superantigen-mediated response. |
| Keren et al.26  | Pseudomonas aeruginosa               | Case report 5-year-old boy, KD with CAL Mitogenic activity by culture and PCR | Pseudomonas infection appeared to be the underlying cause of both the clinical symptoms and the pathological changes of Kawasaki disease. |
| Normann et al.27 | Chlamydiae pneumoniae               | Case report 8-year-old boy Immunohistochemical study for tissue | First report about the demonstration of C. pneumoniae in cardiovascular tissues from children with KD |
| Tang et al.28   | Mycoplasma pneumoniae               | Prospectively analysis of clinical records 450 Patients with KD (2012-2014) | MP infections are found in an important proportion of the KD patients (13.8 % in our series). |

KD, Kawasaki disease; SPEB, streptococcal pyogenic exotoxin B; SPEC, streptococcal pyogenic exotoxin C; GAS, group A Streptococcus; CAL, coronary artery lesion; PCR, polymerase chain reaction; MP, Mycoplasma pneumoniae.
Meanwhile, Song et al. reported a significantly higher positive rate of adenovirus antibodies than the control group. Wang et al. summarized that various common pathogens, mainly bacterial toxins and viral antigens, act as external superantigens in susceptible hosts, causing several diseases such as KD, toxic shock syndrome, and rheumatoid arthritis. In a study of previous or concurrent infections in patients with KD, Fernández-Cooke et al. reported that 17.2% of patients had recent previous infections within the last 4 weeks, while 16.3% had microbiologically confirmed infections in the acute phase. They also emphasized that a standard protocol for microbial testing should be prepared to identify actual infections in patients with KD.

Examples of studies that estimate fungi as the cause of KD include the development of KD-like animal models by Takahashi et al. that induced vasculitis in mice with Candida albicans extracts and that by Rodó et al. that studied the relationship between KD and Candida species. Rodó et al. explained the seasonal cluster phenomenon of KD as the possibility of aerosol transmission by Candida species via tropospheric winds.

These numerous reports imply that various pathogens are a potential cause of KD. Nevertheless, conclusive evidence that infections by these individual pathogens cause KD is lacking, and the possibility of concurrent infections has not been completely excluded.

**Studies of association of KD and viral infection**

In the theory of KD caused by infectious pathogens, bacteria were mainly mentioned first, but interest has gradually shifted toward viruses. The association between viruses and KD has been steadily attracting attention. Speculation that a viral infection could be a KD etiology was triggered by the occurrence of seasonal outbreaks reported in Japan in 1979, 1982, and 1986. In the case of KD accompanied by viral infection, the virus is suspected to be the etiology as follows: Epstein-Barr virus (EBV), parvovirus, dengue virus, varicella-zoster virus, human immunodeficiency virus, human bocavirus, human adenovirus, human coronavirus OC43/HKU1, parainfluenza virus type 3, torque teno virus, and influenza A. These reports are cases in which an infection with a related pathogen was confirmed in various samples extracted from patients treated for KD, but the possibility of accidental coinfections cannot be ruled out regardless of KD status. In case-control studies of viruses as the etiology of KD, adenovirus, human herpesvirus 6, rotavirus, and human coronavirus (HCoV) were reported. Okano et al. reported that patients with KD with 2 outbreaks in 1982 and 1985 had a significantly higher positive rate of adenovirus antibodies than the control group. Meanwhile, Song et al. emphasized that if adenovirus is detected incidentally in KD, it is necessary to carefully distinguish it from acute adenovirus infection itself. This is because human adenovirus is accompanied by long-term fever, skin rash, and increased inflammatory markers in children that can cause clinical characteristics very similar to those of KD. Okano et al. reported that the human herpesvirus 6 antibody positivity rate was higher in 22 patients with KD than in 16 age-and sex-matched healthy controls. Matsuno et al. reported that the positive rate of rotavirus antibodies was significantly higher in 75 KD patients and 39 age-matched controls. Shirai et al. reported that HCoV-229E was more likely involved in the development of KD than HCoV-NL63 using immunofluorescence assays and virus neutralization tests. However, Choe et al. analyzed nationally representative data from 2016–2019 in Korea and reported that seasonal variations in the frequencies of HCoV were not significantly associated with the incidence of KD. Quiat et al. reported no serological evidence that KD patients were exposed to 58 known viruses compared to controls in the acute and subacute stages of KD.

Epidemiologically, although some differences exist among countries, Uehara and Belay reported that KD occurs in clusters and community-wide outbreaks with distinct seasonality, indicating that KD can be caused by infectious agents such as viruses or agents that remain elusive. Similar results were reported of epidemiological investigations of big data by Korean researchers, suggesting that respiratory viruses may be causative pathogens that trigger KD among viral infections. Lim et al. reported that several viruses, including human respiratory syncytial virus, rotavirus, norovirus, and human rhinovirus, precede KD by 1–2 months in the same cycle as the trend of KD diagnosis in a study of big data in Korea, supporting the possibility that the virus is the major cause of KD. Kang et al. reported a cohort study of a time series analysis of children and youth in South Korea with KD, stating that respiratory infections caused by rhinovirus and respiratory syncytial virus as well as varicella outbreaks were significantly correlated with KD at 1–3 months before KD outbreaks. Aguirre et al. reported a direct temporal correlation between respiratory syncytial viruses, influenza A, influenza B, metapneumovirus circulation, and KD through an ecological study of respiratory viruses in Chile in 2010–2017. Table 4 summarizes the major studies of viruses as KD-associated pathogens.

Rowley et al. reported that CD8 T cells, oligoclonal A, and the upregulation of cytotoxic T cell and interferon pathway genes in the coronaries in fatal KD, or identifying cytoplasmic inclusion bodies in ciliated bronchial epithelium, supports a viral etiology, especially of RNA-associated viruses. However, since this requires a highly invasive tissue biopsy in KD patients and advanced molecular techniques, easier and safer tissue sampling methods should be performed.

Farahmand et al. recently attempted the first systematic review and meta-analysis to investigate the association between different viral infections and KD development. Although some limitations exist in that their research data for acute KD and
| Study | Viruses | Study details | Results/conclusions |
|-------|---------|---------------|---------------------|
| Okano et al. (1990) | Adenovirus, Herpes simplex virus type 1 & 2 (HSV-1 & HSV-2), Varicella-zoster virus (VZV), Cytomegalovirus (CMV) | Retrospective study Two outbreaks of KD at different times and areas (12 patients Kyoto in 1982 and 10 Sapporo in 1985), Antibody detection by CF and ELISA | Two of 12 (16.7%) in 1982 and 1 of 10 (10.0%) in 1985 showed positive antibodies for the common adenovirus antigen by CF test. By ELISA test, 9 of 12 (75.0%) in 1982 and 9 of 10 (90.0%) in 1985 had antibodies to adenovirus type 2. No significant difference HSV-1 and HSV-2, VZV, and CMV between patients and controls. |
| Rosenfeld et al. (2020) | Epstein-Barr virus (EBV) | Case report 19-month-old boy KD with a concomitant primary EBV infection | Concomitant EBV infection was supported by positive serology for acute EBV infection (positive IgM VCA EBV antibodies). |
| Holm et al. (1995) | Parvovirus B19 | Case report 9-week-old boy | Serologically diagnosed parvovirus B19 infection in KD patients supports the hypothesis of an etiological relationship between parvovirus B19 infection and KD. |
| Okano et al. (1989) | Human herpesvirus 6 | Case-control study 22 patients with KD, and 16 age- and sex-matched healthy controls | Eighteen of 22 (81.8%) with KD were positive for immunoglobulin G or M antibodies to human herpesvirus 6, whereas 10 of 16 age- and sex-matched healthy controls (62.5%) were seropositive. Human herpesvirus 6 infection may be a reflection of the immunologic alterations that are associated with KD. |
| Matsuno et al. (1983) | Rotavirus | Case-control study Serology test for 75 patients with KD and 39 age-matched healthy controls | A significant increase in antibody to rotavirus was 38 cases (50.7%) in KD, otherwise 3 cases (7.8%) in controls. |
| Singh et al. (2009) | Dengue virus | Case report 8-year-old boy Dengue IgM antibody(+), developed findings consistent with KD | A child presenting with fever and rash, can have more than one underlying condition. |
| Lee et al. (2004) | Varicella-zoster virus | Case report 4-year-old & 5-year-old (sisters) | Two sisters showed a characteristic feature of KD immediately after a primary infection by VZV. VZV infection may cause severe complication and may be associated with KD. |
| Belostotsky et al. (2004) | Human immunodeficiency virus (HIV) | Case report 14-year-old boy with advanced perinatal HIV infection | Atypical KD with coronary artery aneurysm formation in an HIV-infected adolescent suggests that KD may occur in patients with immunodeficiency. |
| Shirato et al. (2014) | Human corona virus (HCoV)-NL63, HCoV-229E | Case-control study 15 Patients with KD and 23 controls & 29 controls, by IF assays and virus neutralizing tests | Serological tests did not support the involvement of HCoV-NL63 but suggested the possible involvement of HCoV-229E in the development of KD. |
| Catalano-Pons et al. (2007) | Human bocavirus (HBoV) | Nasopharyngeal, serum or stool samples from 16 patients with KD by PCR | HBoV was identified in 5 patients (31.2%) by PCR, suggesting that this virus may also play a pathogenic role in some cases of KD. |
| Giray et al. (2016) | Adenovirus, HCoV-OC43/HKU1, Parainfluenza virus type 3 | 4 cases report | Adenovirus in 4-year-old boy & 3-year-old boy, HCoV-OC43/HKU1 in 17-month-old girl Parainfluenza virus type 3 in 4-year-old girl |
| Song et al. (2016) | Adenovirus | Comparative study 31 Patients with KD | Twenty-four of 25 children with adenovirus disease and mimicking features of KD had <4 KD-like features Parafluevirus infection possibly play a role in KD |
| Thissen et al. (2018) | Torque teno virus(TTV) 7 | Case-control study 11 Patients with KD and 22 controls | Sanger sequencing revealed that the TTV 7 found in the 2 KD patients contained almost identical variants in nucleotide and identical changes in resulting amino acid, relative to the reference sequence |
| Wang et al. (2019) | Influenza A (H1N1) pdm09 | Case report 19-month-old boy | More attention should be paid to the correlation between KD and pathogen infection, especially the new influenza virus H1N1. |
| Choe et al. (2020) | HCoV | Big data analysis(2016-2019) Using national representative data from sentinel surveillance and the Health Insurance Review & Assessment Service | Cumulative association of KD per 10% increase of HCoV over 1 month-lag was 0.50 (95% CI, 0.16-1.53), suggesting that seasonal variation in the frequencies of HCoV was not significantly associated with the incidence of KD. |
| Quiat et al. (2020) | 58 viruses | Detection of antiviral antibodies in KD patients and matched controls, Comprehensive serological profiling using a high-throughput PhiP-seq, assay | No differences in antiviral antibody profiles. In the acute and subacute phases of disease, there is no serological evidence that KD patients are exposed to known viruses than controls. |
most studies were conducted in Japan, they found that human parvovirus B19 viremia (odds ratio [OR], 41.05; 95% confidence interval [CI], 5.13–328.28; 95% seropositivity [CI], 3.65–14.12; 95% seropositivity [CI], 1.06–32.01) were highly suggested as key contributors to the development of KD in children. They also hypothesized that KD is not caused by a single viral pathogen but is likely due to multiple viral pathogen infections.

Meanwhile, the relationship between KD and vaccination has also been reported for hepatitis A, hepatitis B, influenza, and rotavirus vaccines. Miron et al. reported KD cases that occurred one day after the second dose of hepatitis B vaccination, and Yin et al. reported that KD occurred after the second dose of hepatitis B vaccine. Although the mechanism underlying the development of KD is not fully understood, there is a possible link between the immune response to vaccines and autoimmunity.
of rotavirus vaccine and the first dose of hepatitis A vaccine at the same time. Shimada et al.\(^6\) raised the possibility of vasculitis due to an autoimmune reaction to an influenza vaccine through a KD case that occurred after receipt of the second dose of influenza vaccine. In particular, Bonetto et al.\(^6\) reviewed 75 studies of various vaccines and vasculitis over 20 years from 1994 to 2014 and reported that the influenza vaccine is more frequently associated with vasculitis than any other vaccine. However, Hua et al.\(^6\) reported no evidence that vaccines increased the risk of KD in 107 cases of KD and 23 U.S. Food and Drug Administration-licensed vaccines across the United States in 1990–2007. Abrams et al.\(^6\) reported that childhood vaccination was related to a decreased incidence of KD by analyzing data from the Vaccine Safety Datalink of the US in 1996–2006. Most recently, Peralta-Amaro et al.\(^6\) reported a case of atypical KD in adults after COVID-19 vaccination (Table 5).

As mentioned above, epidemiological and pathological studies have proposed viruses as the most attractive etiology of KD, but consistent evidence is lacking that any particular virus is the etiology, so research on this topic should continue.

### COVID-19 and KD

Verdoni et al.\(^3\) initially reported that 10 cases of KLD occurred in just 2 months in Bergamo, Italy, the city hardest hit by COVID-19, increasing by 30-fold compared to 19 cases in the immediately preceding 5 years. Since then, many countries in Europe reported a series of positive responses to SARS-CoV-2 infection in patients with KLD,\(^69-72\) raising questions about whether there is a connection between KD and COVID-19. Jones et al.\(^6\) reported a positive case of COVID-19 in 6-month-old infants with classic KD, and Cazzaniga et al.\(^70\) reported a positive case in a 6-year-old boy. Renganathan et al.\(^71\) reported an interesting case of KD recurrence after COVID-19 infection in a 10-year-old boy with a history of KD 4 years prior. Riphagen et al.\(^72\) reported an unprecedented cluster of 8 children with hyperinflammatory shock, showing features similar to atypical KD, KD shock syndrome (KDSS), or toxic shock syndrome (TSS), during a 10-day period in mid-April 2020, 4 of whom had a family history of COVID-19.

On the other hand, in Asia, the KD prevalence decreased during the same period, raising the same issue of the connection between KD and viral infections, which was assumed to be the effect of thorough social distancing or mask wearing.\(^4,6\) Kang et al.\(^4\) reported a reduction in KD after nonpharmaceutical intervention through an ecological study. Ae et al.\(^5\) reported that the incidence of KD in 2020 decreased by 35% versus the previous 3 years (2017–2019) in Japan; in Taiwan, Yang and Kuo\(^6\) reported that, in 2020, Taiwan decreased by 30% and 31% compared to 2018 and 2019, respectively. However, the fact that the number of patients with KD or KLD varies widely among regions before and after the COVID-19 pandemic can be a result of differences in regional policies on infectious diseases affecting healthcare access. In other words, the decrease in KD prevalence in Asia may have been an underestimation caused by the COVID-19 pandemic, which reduced access to healthcare. Therefore, further studies are required in the future.

### Table 6. Comparison of multisystem inflammatory syndrome in children (MIS-C), severe COVID-19 disease without MIS-C, toxic shock syndrome (TSS), and Kawasaki disease (KD)

| Characteristics                  | MIS-C | Severe COVID-19 without MIS-C | TSS | KD |
|---------------------------------|-------|------------------------------|-----|----|
| **Age**                        | 8–10 Years | Adolescents                  | >10 Years | <5 Years |
| **Sex**                        | Male > female | Male = female               | Male < female | Male > female |
| **Etiology**                   | Suspected by SARS-CoV-2 | History of contact with an individual having COVID-19 infection in cases of sero-negative patients | SARS-CoV-2 | Focus of staphylococcal or streptococcal infection | No definite identifiable cause |

#### Clinical manifestations

|                | Present | Present | Present | Present |
|----------------|---------|---------|---------|---------|
| **Fever**      |         |         |         |         |
| **Cutaneous signs** | Similar to KD | Usually absent | Enytherodermia and petechiae | Less common |
| **Lymphopenopathy** | Not common | Not known | Less common | More common |
| **Hemodynamic instability** | Almost all | In case of multiorgan dysfunction | Usually present | Less than 5% |
| **Cardiac complications** | Myocarditis, pericarditis | Usually not seen | Myocardial dysfunction | CAL/Aneurysm |
| **Gastrointestinal symptoms** | Prominent (>80%) | Less common | Not common | Not common |
| **Organ dysfunction** | Multorgan dysfunction | ARDS, MAS, shock are common | Renal and central nervous system | Not common |
| **Laboratory findings** | Lymphopenia, cytokine storm 70%–90% | Lymphopenia, neutropenia Nearly 90% | Neutrophilic leukocytosis No data | Neutrophilic leukocytosis Lack of data |
| **Anti-HCoV antibodies** | IVIG, steroids, IL-1 blockers, IL-6 inhibitors | Antiviral agents, antibiotics, IVIG, steroids, IL-6 inhibitors | Antibiotics, IVIG | IVIG, steroid, IL-1 blockers |

COVID-19, coronavirus disease-2019; SARS-CoV-2 Severe acute respiratory syndrome coronavirus-2; ARDS, acute respiratory distress syndrome; MAS, macrophage activation syndrome; CAL, coronary artery lesion; IVIG intravenous immunoglobulin; IL, interleukin.

Modified from Kabeerdoss et al. Rheumatol Int 2021;41;19-32.\(^7\)
The curiosity about the association between COVID-19 and KD began with reports of clinical features similar to KD, although it sometimes showed a critical course.\(^73,74\) This is more often reported in areas where COVID-19 is highly prevalent,\(^75\) but the new syndrome differs from actual KD; therefore, the World Health Organization and the Centers for Disease Control and Prevention of the US termed it MIS-C.\(^76\) MIS-C is more common in older age groups than KD; the most frequent clinical features are gastrointestinal or neurological symptoms, and shock is also common, making it difficult to consider it the same disease.\(^48,77-81\)

Although there are some overlapping clinical manifestations of COVID-19 and KD, there are also clear distinctions. In South Korea, Kim et al.\(^78\) reported the first case of MIS-C related to COVID-19 in an 11-year-old boy with clinical features of incomplete KD or KDSS in 2020.

Based on the data published thus far, MIS-C, severe COVID-19 infection without MIS-C, TSS, and KD are compared in Table 6. Notably, Rhim et al.\(^80\) recently introduced the hypothesis that similar diseases associated with infection are based on a common immunopathogenesis, the “protein-homeostasis-system,” although clinical manifestations appear in various forms. In particular, this hypothesis is a new concept of the immune response that occurs in an individual, not only by the pathogen itself but by host cells damaged by infection, and is expected to

### Table 7. Summary of studies of SARS-CoV-2 infection and Kawasaki disease

| Study                        | Study details                        | Results/conclusions                                                                 |
|------------------------------|--------------------------------------|--------------------------------------------------------------------------------------|
| Jones et al.\(^59\) (2020)   | Case report: 6-month-old infant with | He also screened positive for COVID-19 in the setting of fever and minimal respiratory symptoms. The patient was treated per treatment guidelines, with IVIG and high-dose aspirin, and subsequently resolution of clinical symptoms without CAL. |
| Cazzania et al.\(^20\) (2020) | Case report: 6-year-old boy with a complete form of KD | PCR tests showed that this patient was infected by enterovirus, rhinovirus, and SARS-CoV-2. It is difficult to understand which of the 3 viral agents had been the trigger. |
| Renganathan et al.\(^71\) (2021) | Case report: 10-year-old boy, who had previously developed KD at 4 years of age | SARS-CoV-2 infection triggered the recurrence of KD in children who might have been genetically predisposed to KD. |
| Riphagen et al.\(^23\) (2020) | Case report: Unprecedented cluster of 8 children with hyperinflammatory shock, showing features similar to atypical Kawasaki disease, KD shock syndrome | This clinical picture represents a new phenomenon affecting previously asymptomatic children with SARS-CoV-2 infection manifesting as a hyperinflammatory syndrome with multiorgan involvement similar to Kawasaki disease shock syndrome |
| Gkoutzourelas et al.\(^73\) (2020) | Review: KD and COVID-19. | MIS-C related to the SARS-CoV-2 pandemic (also termed Kawasaki-like disease, or Kawasaki-COVID) appears to share clinical, pathogenetic and laboratory features with KD, toxic shock syndrome, and MAS. |
| Sancho-Shimizu et al.\(^74\) (2021) | Review: SARS-CoV-2 related MIS-C | SARS-CoV-2 is the trigger for MIS-C, which typically occurs about 1 month after infection. Suggest that rare inborn errors of immunity altering the immune response to SARS-CoV-2 may underlie the pathogenesis of MIS-C in some children |
| Verdoni et al.\(^3\) (2020) | Observational cohort study: Kawasaki-like disease incidence: before (group 1, 5 years) or after (group 2, 2 months) SARS-CoV-2 pandemic | Thirty-fold increased incidence of Kawasaki-like disease: 19 patients in group 1, 10 patients in group 2. SARS-CoV-2 epidemic was associated with high incidence of a severe form of Kawasaki disease |
| Kang et al.\(^4\) (2021) | Retrospective ecologic study: KD incidence decreased significantly after the implementation of nonpharmacological interventions in Korea | During the social distancing period in 2020, KD was approximately 35% lower than in 2017-2019. The weekly reduction in patient numbers differed between KD and PIDs during 2020, with no strong correlation between the 2 diseases. However, these findings indicate the possibility that triggering KD might be associated with unidentified respiratory pathogens. |
| Ae et al.\(^5\) (2021) | Epidemiologic study: Association between KD and common pediatric infectious diseases (PIDs) during COVID-19 | Compared with the 2018 and 2019 databases, KD incidence decreased significantly by 30% and 31%, respectively (P<0.05) in 2020, when public health interventions were comprehensively implemented in Taiwan. Is KD a preventable disease? |
| Yang and Kuo\(^6\) (2021) | Retrospective case series study: Patients with KD between 2018 and 2020 were included for trend analysis | KD incidence decreased significantly after the implementation of nonpharmacological interventions in Korea |
| Kim et al.\(^7\) (2020) | Case report: 11-year-old boy with MIS-C related COVID-19 | The first case in Korea. The child fully recovered after treatment corresponding to KDSS. |
| Kabeerdoss et al.\(^79\) (2021) | Review: MIS-C caused by SARS-CoV-2 | Clinical manifestations of MIS-C mimic KD shock syndrome. MIS-C develops 4-6 weeks following SARS-CoV-2 infection, and is presumably initiated by adaptive immune response. |
| Rhim et al.\(^80\) (2022) | Review: Severe COVID-19, KD, and MIS-C | Immunopathogenesis is similar among these diseases and suggests that the host's common regulatory system may act for each insult |
| Xu et al.\(^81\) (2020) | Comment: Potential link between COVID-19 and KD | SARS-CoV-2 infection and hyperinflammation in COVID-19 could be acting as the "priming trigger" that could lead to KD |

SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; KD, Kawasaki disease; COVID-19, coronavirus disease 2019; IVIG intravenous immunoglobulin; CAL, coronary artery lesion; MIS-C, multisystem inflammatory syndrome in children; MAS, macrophage activation syndrome; KDSS, Kawasaki disease shock syndrome.
bring new implications for the ongoing study of KD etiology.

However, Xu et al. hypothesized that MIS-C due to SARS-CoV-2 infection acts as a “priming trigger,” leading to KD, as strong systemic inflammatory reactions may trigger coronary lesions. Xu et al. also estimated that the absence of reported KD or KD-like symptoms observed in pediatric patients in China since the COVID-19 outbreak was due to differences in racial backgrounds and genetic susceptibilities. Unlike in Europe, in Korea, Japan, and Taiwan, the prevalence of KD decreased during the COVID-19 pandemic. This phenomenon is attributed to a decrease in respiratory infections caused by thorough social distancing and mask wearing measures, which strongly suggests that the etiology of KD is related to unidentified respiratory pathogens. This not only reminds us of the importance of ethnic background differences or strengthening respiratory infection control, it suggests that KD can be triggered by more diverse pathogens rather than a single causative pathogen. Table 7 summarizes case reports of SARS-CoV-2 infection as a KD-related pathogen and studies of its association.

Conclusion

If the etiology of a disease is unclear, it obscures its prevention, diagnosis, and management. KD can cause serious sequelae in young children in particular; therefore, continuous efforts to determine its etiology are essential. Thus far, the virus has attracted great attention as one etiology of KD, but it remains difficult to identify a single causative pathogen. The role of the virus in KD pathophysiology or identification of the virus as a direct etiology is expected to be clarified through the development of more advanced diagnostic technologies in the future. However, there is no significant disagreement regarding the pathophysiology of KD in that infection with various pathogens, including viruses, triggers a strong inflammatory response in individuals from certain genetic backgrounds. Therefore, in the future, it will be necessary to conduct continuous research on immune responses in patients with KD, including their genetic backgrounds, and identify KD causative factors, including various pathogens.

Footnotes

Conflicts of interest: No potential conflict of interest relevant to this article was reported.

Funding: This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID:
Young Hwan Lee https://orcid.org/0000-0001-8377-5802

References

1. Nagata S. Causes of Kawasaki disease-from past to present. Front Pediatr 2019;7:18.
2. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Anerugi 1967;16:178-222.
3. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciufrreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020;395:1771-8.
4. Kang JM, Kim YE, Huh K, Hong J, Kim DW, Kim MY, et al. Reduction in Kawasaki disease after nonpharmacological interventions in the COVID-19 era: a nationwide observational study in Korea. Circulation 2021;143:2508-10.
5. Aae R, Shihata Y, Kosami K, Nakamura Y, Hamada H. Kawasaki disease and pediatric infectious diseases during the coronavirus disease 2019 pandemic. J Pediatr 2021;239:50-8.e2.
6. Yang YL, Kuo HC. Public health interventions for COVID-19 reduce Kawasaki disease in Taiwan. Children (Basel) 2021;8:623.
7. Choi JW. Can we get a clue for the etiology of Kawasaki disease in the COVID-19 pandemic? Clin Exp Pediatr 2020;63:335-6.
8. Kwak JH, Lee SY, Choi JW. Korean Society of Kawasaki Disease. Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019. Clin Exp Pediatr 2021;64:68-75.
9. Kok HC, Nair D, Wong KJ, Fong SM. Multisystem inflammatory syndrome in children and Kawasaki disease in infants: 2 sides of the same coin? Clin Exp Pediatr 2021;64:599-601.
10. Feldstein LR, Rose EB, Horwitz SM, Collins JR, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020;383:334-46.
11. Fabbri M, Ficile E, Andreozzi L, Conti F, Gabrielli L, Balducci A, et al. Spectrum of cardiovascular diseases in children during high peak coronavirus disease 2019 pandemic period infection in Northern Italy: is there a link? J Pediatric Infect Dis Soc 2021;10:714-21.
12. Swann OV, Holden KA. Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with COVID-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 2020;370:m3249.
13. Fujita Y, Nakamura Y, Sakata K, Hara N, Kobayashi M, Nagai M, et al. Kawasaki disease in families. Pediatrics 1989;94:666-9.
14. Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Clinical features of patients with Kawasaki disease whose parents had the same disease. Arch Pediatr Adolesc Med 2004;158:1166-9.
15. Makino N, Nakamura Y, Yashiro M, Kosami K, Matsubara Y, Ae R, et al. Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. Pediatr Int 2019;61:397-403.
16. Yanagawa H, Nakamura Y, Kawasaki T, Shigematsu I. Nationwide epidemic of Kawasaki disease in Japan during winter of 1985-86. Lancet 1986;2:1138-9.
17. Lim JH, Kim YK, Min SH, Kim SW, Lee YH, Lee JM. Seasonal trends of viral prevalence and incidence of Kawasaki disease: a Korea public health data analysis. J Clin Med 2021;10:3301.
18. Kang JM, Jung J, Kim YE, Huh K, Hong J, Kim DW, et al. Temporal correlation between Kawasaki disease and infectious diseases in South Korea. JAMA Netw Open 2022;5:e2147363.
19. Rowley AH. Is Kawasaki disease an infectious disorder? Int J Rheum Dis 2018;21:20-5.
20. Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secretin Staphylococcus aureus in Kawasaki syndrome. Lancet 1993;342:1385-8.
21. Wann ER, Fehringer AF, Ezechuk YV, Schlievert PM, Bina P, Reiser RF, et al. Staphylococcus aureus isolates from patients with Kawasaki disease express high levels of protein A. Infect Immun 1999;67:4737-43.
22. Matsubara K, Fukaya T. The role of superantigens of group A Streptococo
A novel variant of torque teno virus 7 identified in patients with Kawasaki disease. PLoS One 2018;13:e0209683.

46. Wang J, Sun F, Deng HL, Liu RQ. Influenza A (H1N1)pdm09 virus infection in a patient with incomplete Kawasaki disease: a case report. Medicine (Baltimore) 2019;98:e15009.

47. Cho SE, An HS, Choe YJ. No temporal association between human coronavirus and Kawasaki disease: national data from South Korea. J Med Virol 2021;93:585-7.

48. Rowley AH, Shulman ST, Arvidt M. Immune pathogenesis of COVID-19-related multisystem inflammatory syndrome in children. J Clin Invest 2020;130:5619-21.

49. Wang CL, Wu YT, Liu CA, Kuo HC, Yang KD. Kawasaki disease: infection, immunity and genetics. Pediatr Infect Dis J 2005;24:998-1004.

50. Fernández-Cooke E, Tascón AB, Antón-López J, Grasa Lozano CD, Sánchez-Manubens J, Calvo C, et al. Previous or coincident infections with suspected Kawasaki disease. Should we change our approach? An Pediatr (Engl Ed) 2019;90:213-8.

51. Quat D, Kula T, Shimizu C, Kanezaya JT, Tremoulet AH, Pirkowski Z, et al. High-throughput screening of Kawasaki disease sera for antiviral antibodies. J Infect Dis 2020;222:1853-7.

52. Aguirre D, Cerda J, Perret C, Borutzky A, Hoyo-Buchiolgo R. Asociación temporal entre la circulación de virus respiratorios y hospitalizaciones por enfermedad de Kawasaki. Temporal association between the circulation of respiratory viruses and hospitalizations due to Kawasaki disease. Rev Chilena Infectol 2021;38:152-60.

53. Takahashi K, Oharaaki T, Naoe S, Yamada H, Muruta H, Wakiyama M, et al. Candida albicans – extract causing systemic vasculitis in mice as an animal model of Kawasaki disease. Pediatr Res 2003;53:175.

54. Rodó X, Curroll R, Robinson M, Ballestor J, Burns JC, Cayan DR, et al. Trophospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proc Natl Acad Sci U S A 2014;111:7952-7.

55. Huang SM, Huang SH, Weng KP, Chien KJ, Lin CC, Huang YF. Update on association between Kawasaki disease and infection. J Chin Med Assoc 2019;82:172-4.

56. Chang LY, Lu CY, Shao PL, Lee PL, Lin MT, Fan TY, et al. Viral infections associated with Kawasaki disease. J Formos Med Assoc 2014;113:148-54.

57. Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol 2012;22:79-85.

58.Rowley AH, Baker SC, Shulman ST, Rand KH, Treviakova MS, Perlm EJ, et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease. J Infect Dis 2011;203:1021-30.

59. Rowley AH, Shulman ST. The epidemiology and pathogenesis of Kawasaki disease. Front Pediatr 2018;6:374.

60. Farahmand M, Ahmadi-Vaseghi R, Asteeghamati A, Sayyahfar S, Minaeian S, Kanhallah K, et al. A meta-analysis on association between viral infections and Kawasaki disease in children. Future Virol 2021;16:27-41.

61. Nakamura A, Ikeda K, Hamaoka K. Aetiological significance of infectious stimuli in Kawasaki disease. Front Pediatr 2019;7:244.

62. Miron D, Fink D, Hashkes PJ. Kawasaki disease in an infant following immunisation with hepatitis B vaccine. Clin Rheumatol 2003;22:461-3.

63. Yin S, Liubao P, Chongqing T, Xiaomin W. The first case of Kawasaki disease in a 20-monthold baby following immunization with rotavirus vaccine and hepatitis A vaccine in China: a case report. Hum Vaccin Immunother 2015;11:2740-3.

64. Shimada S, Watanabe T, Sato S. A patient with Kawasaki disease following influenza vaccinations. Pediatr Infect Dis J 2015;34:913.

65. Bonetto C, Trotta F, Felicetti P, Alarcón GS, Santuccio C, Bachtir NS, et al. Vasculitis as an adverse event following immunization - systematic literature review. Vaccine 2016;34:6641-51.

66. Hua W, Izuirieta HS, Slade B, Belay ED, Haber I, Tiernan R, et al. Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007. Pediatr Infect Dis J 2009;28:943-7.

67. Abrams JY, Weintraub ES, Baggis JM, McCarthy NL, Schonberger LB,
Lee GM, et al. Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. Vaccine 2015;33:382-7.

68. Peralta-Amaro AL, Tejada-Ruiz MI, Rivera-Alvarado KL, Cobos-Quevedo OJ, Romero-Hernández P, Maclías-Arroyo W, et al. Atypical Kawasaki disease after COVID-19 vaccination: a new form of adverse event following immunization. Vaccines (Basel) 2022;10:126.

69. Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Segal JB, et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr 2020;10:537-40.

70. Cazzaniga M, Baselli LA, Cimaz R, Guzz SS, Pinzani R, Dellepiane RM. SARS-COV-2 Infection and Kawasaki disease: case report of a hitherto unrecognized association. Front Pediatr 2020;8:398.

71. Renganathan A, Garg A, Chowdhary S, Raj D. SARS-CoV2 infection triggering recurrence of Kawasaki disease in a 10-year-old child. BMJ Case Rep 2021;14:e240972.

72. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395:1607-8.

73. Gkoutzourelas A, Bogdanos DP, Sakkas LI. Kawasaki disease and COVID-19. Mediterr J Rheumatol 2020;31(Suppl 2):268-74.

74. Sancho-Shimizu V, Brodin I, Cobat A, Biggs CM, Toubiana J, Lucas CL, et al. SARS-CoV-2-related MIS-C: a key to the viral and genetic causes of Kawasaki disease? J Exp Med 2021;218:e20210446.

75. Kim L, Whitaker M, O’Halloran A, Kambhampati A, Chai SJ, Reingold A, et al. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 - COVID-NET, 14 states, March 1-July 25, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1081-8.

76. Lee JK, Cho EY, Lee H. Multisystem inflammatory syndrome in children. Pediatr Infect Vaccine 2021;28:66-81.

77. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidas SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol 2020;72:1791-805.

78. Kim H, Shim JY, Ko JH, Yang A, Shim JW, Kim DS, et al. Multisystem inflammatory syndrome in children related to COVID-19: the first case in Korea. J Korean Med Sci 2020;35:e391.

79. Kabeerdoss J, Pilania RK, Karvekele R, Kumar SA, Danda D, Singh S. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management. Rheumatol Int 2021;41:19-32.

80. Rhim JW, Kang JH, Lee KY. Etiological and pathophysiological enigmas of severe coronavirus disease 2019, multisystem inflammatory syndrome in children and Kawasaki disease. Clin Exp Pediatr 2022;65:153-66.

81. Xu S, Chen M, Weng J. COVID-19 and Kawasaki disease in children. Pharmacol Res 2020;159:104951.

How to cite this article: Lee YH. Research trends on causes of Kawasaki disease in the COVID-19 era: focus on viral infections. Clin Exp Pediatr 2023;66:1-11.